BLT
Click for more information
0.00% 2.6¢ benitec biopharma limited

time for a reality check, page-50

  1. spendit
    4,112 Posts.
    lightbulb Created with Sketch. 185
    clock Created with Sketch.
    15/09/14
    14:31
    Post #: 13976067
    It's a the trial protocol. Its a safety study. So all needs to be handled to a certain degree of set procedures.

    http://www.aspectfinancial.com.au/d...Jyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true

    Approval by the Data Safety Monitoring Board (DSMB) to proceed with the clinical trial with no
    modification following review of the safety parameters of the first patient after 6 weeks
    following the single administration.

    http://www.aspectfinancial.com.au/d...Jyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true


    I like the Blue rose max. Nice touch.
    Last edited by spendit: 15/09/14
    BLT Price at posting: $1.05 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Buying smarter as baby boomers get boost
right-arrow Created with Sketch.
TX3 Canadian fieldwork yields multiple pegmatites for Trinex
right-arrow Created with Sketch.
FWD Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
right-arrow Created with Sketch.
SKS SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
right-arrow Created with Sketch.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
GED Golden Deeps eyes prospective Cu-Au tenements in NSW with HOA
right-arrow Created with Sketch.
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.